Edwards Lifesciences Corporation $EW Shares Acquired by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 9.6% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 81,782 shares of the medical research company’s stock after buying an additional 7,141 shares during the period. Oppenheimer & Co. Inc.’s holdings in Edwards Lifesciences were worth $6,360,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Linden Thomas Advisory Services LLC boosted its stake in Edwards Lifesciences by 2.2% in the third quarter. Linden Thomas Advisory Services LLC now owns 11,646 shares of the medical research company’s stock valued at $906,000 after acquiring an additional 246 shares during the period. Wilson Asset Management International PTY Ltd. raised its position in shares of Edwards Lifesciences by 2.3% during the 3rd quarter. Wilson Asset Management International PTY Ltd. now owns 149,823 shares of the medical research company’s stock worth $11,652,000 after purchasing an additional 3,317 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Edwards Lifesciences by 57.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 37,880 shares of the medical research company’s stock worth $2,946,000 after purchasing an additional 13,820 shares during the last quarter. Candriam S.C.A. boosted its position in Edwards Lifesciences by 6.0% during the 3rd quarter. Candriam S.C.A. now owns 61,990 shares of the medical research company’s stock valued at $4,821,000 after purchasing an additional 3,505 shares during the period. Finally, Azzad Asset Management Inc. ADV boosted its position in Edwards Lifesciences by 330.5% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock valued at $1,651,000 after purchasing an additional 16,296 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 43,804 shares of company stock valued at $3,699,082. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Up 0.3%

EW stock opened at $77.00 on Wednesday. The firm’s 50-day moving average is $83.83 and its two-hundred day moving average is $81.14. The company has a market capitalization of $44.68 billion, a price-to-earnings ratio of 33.19, a price-to-earnings-growth ratio of 2.96 and a beta of 0.94. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the business earned $0.59 earnings per share. The company’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Company forecast and outlook: Edwards said 2026 profit would come in above Street estimates, citing strong demand for its artificial heart valves and other devices — this outlook lifted sentiment and contributed to an after-hours rally. Edwards forecasts 2026 profit above estimates
• Positive Sentiment: Q1 2026 guidance topped EPS consensus: management set Q1 EPS at $0.70–$0.76 versus consensus ~$0.69, and guided revenue roughly in line with expectations — this makes near-term earnings trajectory slightly firmer.
• Positive Sentiment: Fourth-quarter revenue and product growth: Q4 sales rose ~13% to $1.57B with TAVR sales up ~12% and TMTT growth >40% (repair/replacement therapies), indicating sustained procedure demand that supports longer-term revenue growth. Edwards Reports Fourth Quarter Results
• Neutral Sentiment: Metric-by-metric view: Analysts and data services note mixed beats/misses — revenue was roughly in line or slightly above some estimates while adjusted EPS missed modestly; dig into adjusted vs. GAAP figures to reconcile differences. Zacks: A Look at Key Metrics
• Negative Sentiment: Profitability and GAAP weakness: reported results show large year-over-year drops in operating profit and net income on a GAAP basis (company reported low GAAP EPS while adjusted EPS was higher), and operating cash flow swung — these items explain market concern and earlier intraday weakness. Quiver’s summary highlights the magnitude of the profit decline and unusual items. Quiver: Stock Falls on Q4 Earnings
• Negative Sentiment: Insider selling and mixed institutional flows: recent disclosure shows multiple insider sales and active reshuffling among large holders, which can add caution for some investors despite strong analyst price targets. Quiver: Insider & Institutional Activity

Analysts Set New Price Targets

Several brokerages have weighed in on EW. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $108.00 target price on shares of Edwards Lifesciences in a research report on Friday, January 9th. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 31st. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Barclays reissued an “overweight” rating and set a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $96.77.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.